Nonsteroidal anti-inflammatory drug gastropathy and Helicobacter pylori: The search for an improbable consensus

American Journal of Medicine

Volumn 110, Issue 1 SUPPL. 1, 2001, Pages S50-S54

  Lazzaroni, M ^a   Bianchi Porro, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; RANITIDINE;

DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DYSPEPSIA; ERADICATION THERAPY; GASTROINTESTINAL HEMORRHAGE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION COMPLICATION; INTESTINE INJURY; PRIORITY JOURNAL; REVIEW; STOMACH MUCOSA LESION; ULCER HEALING; UPPER GASTROINTESTINAL TRACT;

EID: 0035825135     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(00)00636-7     Document Type: Review

References (42)

1. Long-term non-steroidal anti-inflammatory drug use and gastroduodenal injury: The role of Helicobacter pylori
2. Chemical gastritis and Helicobacter pylori related gastritis in patient receiving non-steroidal anti-inflammatory drugs: Comparison and correlation with peptic ulceration
3. Prevalence of Helicobacter pylori and its effect on symptoms and non-steroidal anti-inflammatory drug-induced gastrointestinal damage in patients with rheumatoid arthritis
4. Seroprevalence of Helicobacter pylori in rheumatoid arthritis patients
5. Non-steroidal anti-inflammatory drug-induced dyspepsia: Is Campylobacter pyloridis implicated?
6. The presence of Campylobacter pylori in non-steroidal anti-inflammatory drug associated gastritis
7. Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking non-steroidal anti-inflammatory drugs
8. Role of non-steroidal anti-inflammatory drugs and Helicobacter pylori in bleeding peptic ulcer
9. Campylobacter pylori associated gastritis in patients with rheumatoid arthritis taking non-steroidal anti-inflammatory drugs
10. Serological evidence of infection with Helicobacter pylori may predict gastrointestinal intolerance to non-steroidal anti-inflammatory drug (NSAID) treatment in rheumatoid arthritis
11. The influence of Helicobacter pylori colonisation and gastroduodenal ulceration in patients on non-steroidal anti-inflammatory drugs
12. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs
13. Effect of Helicobacter pylori infection on the severity of gastroduodenal mucosa injury after the acute administration of naproxen or aspirin in normal volunteers
14. Interrelationships between Helicobacter pylori infection, non-steroidal anti-inflammatory drugs and gastroduodenal disease
15. Helicobacter pylori: A risk and severity factor of non-steroidal anti-inflammatory drug inducted gastropathy
16. Non-steroidal anti-inflammatory drugs (NSAID) cause gastrointestinal ulcers mainly in Helicobacter pylori carriers
17. Campylobacter pylori, NSAIDs, and smoking risk factors for peptic ulcer disease
18. The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly
19. Campylobacter like organisms, non-steroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis
20. Helicobacter pylori infection increases the risk of peptic ulcer in chronic users on non-steroidal anti-inflammatory drugs
21. Long term non-steroidal anti-inflammatory drug use and Helicobacter pylori infection
22. Helicobacter pylori infection in elderly people: Correlation between histology and serology
23. Ulcer risk factors: Interactions between Helicobacter pylori infection, non-steroidal use and age
24. H. pylori infection increases the risk of non-steroidal anti-inflammatory drug (NSAID) induced gastroduodenal ulceration
25. Mucosal erosions in long term non-steroidal anti-inflammatory drug users: Predisposition to ulceration and relation to H. pylori
26. No evidence of H. pylori-NSAID interaction in ulcer formation: Results of double blind, placebo controlled trials
27. Helicobacter pylori infection and the development of gastric and duodenal ulcer in arthritic patients receiving chronic NSAID therapy
28. Omeprazole compared with misoprostol for ulcers associated with non-steroidal anti-inflammatory drugs
29. A comparison of omeprazole with ranitidine for ulcer associated with non-steroidal anti-inflammatory drugs
30. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers
31. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in long-term NSAID users: Response to omeprazole dual therapy
32. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study
33. Ulcer site and complications: Relation to Helicobacter pylori infection and NSAID use
34. The prevalence of Helicobacter pylori and NSAID use in patients with UGI haemorrhage and their potential role in recurrence of ulcer bleeding
35. Helicobacter pylori increases the risk of peptic ulcer bleeding: A case-control study
36. Helicobacter pylori and acute bleeding peptic ulcer
37. Helicobacter pylori and risk of ulcer bleeding among users of non-steroidal anti-inflammatory drugs: A case control study
38. Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: A case control study
39. Differing prevalence of Helicobacter in bleeding and nonbleeding ulcers
40. Interaction of risk factors for peptic ulcer bleeding
41. Eradication of H. pylori versus maintenance acid suppression to prevent recurrent haemorrhage in high risk NSAID users: A prospective randomised study
42. Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection